Trial Profile

A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 (Umbralisib) in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK or PI3K-Delta Inhibitor Therapy

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 16 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Umbralisib (Primary)
Indications Chronic lymphocytic leukaemia
Focus Therapeutic Use
Sponsors TG Therapeutics Inc

Most Recent Events

03 Jul 2024 Status changed from completed to discontinued. (Reason the study was stopped:Strategic/Business Decision)
19 Jul 2021 Status changed from active, no longer recruiting to completed.
05 May 2021 Planned End Date changed from 1 Jun 2021 to 1 Jul 2021.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com